The PSMC4 antibody targets the Proteasome 26S Subunit, ATPase 4 (PSMC4), a critical component of the 19S regulatory particle within the 26S proteasome complex. The 26S proteasome is responsible for ubiquitin-dependent protein degradation, a process essential for maintaining cellular homeostasis, regulating cell cycle progression, and eliminating misfolded or damaged proteins. PSMC4. also known as Rpt3. is one of six AAA-ATPase subunits in the 19S complex, which facilitates substrate recognition, deubiquitination, and unfolding of target proteins before their translocation into the proteolytic 20S core.
PSMC4 plays a vital role in ATP hydrolysis, providing energy for the assembly and function of the 26S proteasome. Dysregulation of PSMC4 has been implicated in various pathologies, including cancer, neurodegenerative diseases, and immune disorders, due to its impact on protein turnover and cellular stress responses. Antibodies against PSMC4 are widely used in research to study proteasome dynamics, protein degradation pathways, and disease mechanisms. They enable detection of PSMC4 expression levels via techniques like Western blotting, immunohistochemistry, and immunofluorescence, as well as functional studies using immunoprecipitation or CRISPR/Cas9-based knockout models. These tools help elucidate the role of PSMC4 in health and disease, offering insights into therapeutic strategies targeting proteasome activity.